The positivity of SPARC indicates that there may be greater delivery of albumin-bound paclitaxel to the malignant sarcoma, since SPARC is a facilitator that allows more chemotherapeutic agents to concentrate in the surrounding tumoral microenvironment [27]. Here, SPARC is linked to sarcoma.